Seelos Therapeutics, Inc.

OTCPK:SEEL.Q Stock Report

Market Cap: US$176.6k

Seelos Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Raj Mehra

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage34.0%
CEO tenure6yrs
CEO ownership0.3%
Management average tenure4.7yrs
Board average tenure6yrs

Recent management updates

Recent updates

Seelos: Data This Year Is Critical

Oct 04

Seelos wins Parkinson’s research grant for gene therapy program

Aug 24

Seelos: FDA Action Makes It Highly Attractive

Dec 22

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

Oct 01

CEO Compensation Analysis

How has Raj Mehra's remuneration changed compared to Seelos Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

US$4m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$2mUS$587k

-US$38m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$2mUS$562k

-US$74m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$61m

Dec 31 2021US$16mUS$523k

-US$66m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$4mUS$475k

-US$19m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$709kUS$438k

-US$51m

Compensation vs Market: Raj's total compensation ($USD1.73M) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.

CEO

Raj Mehra (64 yo)

6yrs

Tenure

US$1,726,476

Compensation

Dr. Raj Mehra, Ph D., J.D., serves as Chairman at Seelos Therapeutics, Inc. and serves as Chief Executive Officer, Director and President of Seelos Therapeutics, Inc. since January 24, 2019. He was an Inde...

Leadership Team

NamePositionTenureCompensationOwnership
Raj Mehra
CEO, Founder6yrsUS$1.73m0.33%
$ 585.6
Michael Golembiewski
Chief Financial Officer3.3yrsUS$846.67k0.16%
$ 275.0
Anthony Marciano
Chief Communications Officer6yrsno datano data
Gopal Krishna
Head of Manufacturing & Technical Operationsno datano datano data
Tim Whitaker
Chief Medical Officerno datano datano data
Karen Fusaro
Senior VP & Head of Clinical Operations2.2yrsno datano data

4.7yrs

Average Tenure

Experienced Management: SEEL.Q's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Raj Mehra
CEO, Founder6yrsUS$1.73m0.33%
$ 585.6
Margaret Dalesandro
Independent Director3.3yrsUS$89.72k0.0021%
$ 3.6
Richard Pascoe
Independent Director11.8yrsUS$87.72k0.00023%
$ 0.4
Brian Lian
Independent Director6yrsUS$105.22k0%
$ 0

6.0yrs

Average Tenure

62yo

Average Age

Experienced Board: SEEL.Q's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:21
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Seelos Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG